Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Benoit Pineau

Gastroenterology St. Augustine, FL Medical Doctor

NPI 1619173309 CMS profile 300169

100 Whetstone Place, Suite 105, St. Augustine, FL 32086

Open in the dashboard

General payments

$41,730

654 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$353,147 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Benoit Pineau of St. Augustine, FL is reported in the CMS Open Payments database as having received $41,730 across 654 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $353,147 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24,515 148
2024 General $4,831 116
2023 General $2,245 116
2022 General $2,061 102
2021 General $5,633 99
2020 General $409 24
2019 General $2,034 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benoit Pineau
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Benoit Pineau were reported at $24,515. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Benoit Pineau Gastroenterology median Middle half National median
2019 $2,034 $417 $126–$1,100 $163
2020 $409 $224 $74–$624 $114
2021 $5,633 $352 $106–$1,054 $132
2022 $2,061 $448 $129–$1,270 $149
2023 $2,245 $533 $150–$1,390 $160
2024 $4,831 $605 $160–$1,606 $164
2025 $24,515 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $20,112 30 payments
  2. AbbVie, Inc. $6,631 144 payments
  3. Genzyme Corporation $2,906 27 payments
  4. Medtronic, Inc. $2,830 29 payments
  5. Boston Scientific Corporation $1,205 11 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $998 53 payments
  7. Janssen Biotech, Inc. $981 72 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $853 54 payments
  9. Allergan Inc. $605 21 payments
  10. Celgene Corporation $478 36 payments
  11. Other $4,130 177 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,062 7 payments
  2. Food and Beverage $13,983 625 payments
  3. Travel and Lodging $2,954 20 payments
  4. Consulting Fee $1,716 1 payment
  5. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology And Inflammation $19,746 14 payments
  2. LINZESS $5,050 60 payments
  3. DUPIXENT Immunology $2,906 27 payments
  4. GI Genius $2,571 27 payments
  5. STELARA $982 56 payments
  6. RINVOQ $842 35 payments
  7. ENTYVIO $708 39 payments
  8. XIFAXAN $609 39 payments
  9. SKYRIZI $600 29 payments
  10. CREON $549 36 payments
  11. Other $8,241 371 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,735

Median for Gastroenterology: 569

Drug cost

$442,803

Median for Gastroenterology: $104,976

Branded share of claims

15.9%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 11 $280,800
Xeljanz Tofacitinib Citrate Brand 12 $71,490
Linzess Linaclotide Brand 53 $41,324
Pantoprazole Sodium Generic 612 $10,011
Omeprazole Generic 299 $5,565
Colestipol Hcl Generic 87 $5,503
Ursodiol Generic 14 $4,402
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 66 $3,839
Famotidine Generic 201 $3,746
Suflave Peg 3350/Sod Sulf,chlr/Pot/Mag Brand 29 $3,547

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$323,814

Of which drugs: $135,794

Medicare patients

794

Average age 75

Services billed

10,030

430 women, 364 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 42%
Diabetes 29%
Chronic kidney disease 26%
Atrial fibrillation 22%
COPD 21%
Depression 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 11 4,800 $83,157
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 15 1,140 $26,701
Infusion, normal saline solution, 250 cc J7050 Office 29 48 $25

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$2,547 — —
SKYRIZI
$200 — —
Sucraid
$195 — —
ENTYVIO
$138 — 4,800
RINVOQ
$135 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

654 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record